Investigating miRNA-661 and ATG4-B mRNA expression as potential biomarkers for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Investigating miRNA-661 and ATG4-B mRNA expression as potential biomarkers for hepatocellular carcinoma

Published:2018-03 Issue:3 Volume:12 Page:245-256
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Ali Mahmoud A¹,Matboli Marwa²,El-Khazragy Nashwa³,Saber Osama⁴,El-Nakeep Sarah⁵,Abdelzaher Hana M⁶,Shafei Ayman El-Sayed¹,Mostafa Randa¹

Affiliation:

1. Department of Biomedical Research, Armed Forces College of Medicine (AFCM), Cairo, 11774, Egypt

2. Department of Medical Biochemistry & Molecular Biology, Ain Shams Faculty of Medicine Research Center (Masri), 11778, Eygpt

3. Department of Clinical Pathology, Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University, Cairo, 11778, Egypt

4. Armed Forces College of Medicine (AFCM), Cairo, 11774, Egypt

5. Hepatology & Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, 11778, Egypt

6. Faculty of Biotechnology, October University for Modern Sciences & Arts, Cairo, 12585, Egypt

Abstract

Aim: We aimed to examine the statistical association between serum expression of miRNA 661 (miR-661) and ATG-4B mRNA and hepatocellular carcinoma (HCC) based on in silico data analysis followed by clinical validation. Patients & methods: Quantitative reverse-transcriptase real-time PCR was used to examine the expression of miR-661 and ATG-4B mRNA in the sera of HCC patients versus control. Results: The expression of miR-661 and ATG-4B mRNA was positive in 97.14 and 77.14%, respectively, in HCC patients. The survival analysis showed that ATG-4B mRNA was an independent prognostic factor. Conclusion: Our data are the first report of its kind regarding the considerable clinical significance of miR-661 and ATG-4B mRNA in HCC patients.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2017-0273

Reference42 articles.

1. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) hepatobiliary cancers. Version 22015 (2015).

2. Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma

3. Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response

4. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment

5. Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic switch selectively kills hepatocellular carcinoma cell based on microRNA and tissue-specific promoter;Molecular and Cellular Probes;2024-10

2. Extracellular Vesicles Contribute to Viral-Induced Hepatocellular Carcinoma: Understanding Their Involvement in Viral Hepatitis and Their Potential as Biomarkers for Early Hepatocellular Carcinoma Detection;Viral Immunology;2024-04-01

3. Circulating MicroRNAs: Diagnostic Value as Biomarkers in the Detection of Non-alcoholic Fatty Liver Diseases and Hepatocellular Carcinoma;MicroRNA;2023-07

4. Post-Translational Modifications of ATG4B in the Regulation of Autophagy;Cells;2022-04-13

5. Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises);World Journal of Gastrointestinal Pathophysiology;2022-01-22